澳洲批准突破性黑色素瘤癌症治療法
Australia approves breakthrough cancer treatment for melanoma
Updated at: June 12, 2026 at 02:45 AM
澳洲在對抗黑色素瘤方面取得了重大進展，由於該國的高紫外線曝露量，此病常被稱為「國病」。
Australia is making significant strides in the fight against melanoma, often referred to as the country’s national cancer due to high UV exposure.
近期，澳洲在癌症護理方面達成了一項指標性的里程碑：核准了新輔助療法，即手術前的合併免疫療法。
Recently, the nation reached a landmark milestone in cancer care: the approval of neoadjuvant, or pre-surgery, combination immunotherapy.
根據由喬治娜·朗(Georgina Long)教授共同領導、成果卓著的NADINA試驗，此策略是在手術前進行治療，而非等待術後。
Based on the successful NADINA trial, co-led by Professor Georgina Long, this strategy involves administering treatment before surgery rather than waiting until afterward.
這種轉變已被證實可將高風險第三期黑色素瘤患者的疾病惡化與死亡風險降低約68%。
This shift has been shown to reduce the risk of disease progression and death by approximately 68% for patients with high-risk Stage III melanoma.
2025年8月1日，此項突破正式列入藥物福利計劃(PBS)，使符合資格的澳洲民眾能以可負擔的價格取得治療。
On August 1, 2025, this breakthrough was officially listed on the Pharmaceutical Benefits Scheme (PBS), making it affordable and accessible for eligible Australians.
在此之外，澳洲亦見證了其他重大進展，例如2024年將Opdualag列入PBS，以及2026年澳洲藥物管理局(TGA)核准了首款用於實體腫瘤的T細胞療法——利菲留細胞(lifileucel)。
Alongside this, Australia has seen other major advancements, such as the 2024 PBS listing of Opdualag and the 2026 TGA approval of lifileucel, the first T-cell therapy for solid tumors.
這些成就突顯了澳洲作為臨床研究全球領導者的地位。
These achievements highlight Australia’s status as a global leader in clinical research.
透過藥物福利計劃，澳洲成功銜接了創新試驗與公共資助，確保這些救命的療法不再只是未來的可能性，而是目前正在對抗晚期黑色素瘤患者的真實選項。
By bridging the gap between innovative trials and public funding through the PBS, Australia is ensuring that life-saving treatments are no longer just future possibilities, but current realities for patients battling advanced melanoma.
